Literature DB >> 17688834

Immunogenicity of biologic agents: a new concern for the practicing rheumatologist?

Boulos Haraoui1, Jean-Pierre Pelletier, Johanne Martel-Pelletier.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17688834     DOI： 10.1007/s11926-007-0042-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  3 in total

1.  Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

Authors:  Boulos Haraoui; Louise Cameron; Michèle Ouellet; Barbara White
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

Review 2.  Fully human therapeutic monoclonal antibodies.

Authors:  Louis M Weiner
Journal:  J Immunother       Date:  2006 Jan-Feb       Impact factor: 4.456

3.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245
  3 in total
  1 in total

Review 1.  B-cell Therapy for Multiple Sclerosis: Entering an era.

Authors:  Ariele L Greenfield; Stephen L Hauser
Journal:  Ann Neurol       Date:  2018-01       Impact factor: 10.422
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.